WNTinib's efficacy was assessed in three animal models (n = 48): (a) patient-derived xenograft (PDX) HB tumors (n = 5 CTNNB1-mutant, n = 1 CTNNB1 wild-type) implanted in NSG mice; (b) PDX-derived TT001- and (c) HepG2-HB cells subcutaneously implanted in Fox1<sup>nu</sup> mice; and in two patient-derived organoids from CTNNB1-mutant HBs. This evidence concerns the gene CTNNB1 and hemoglobin measurement.